PARP1 and ovarian carcinoma: In March 2017, following a report from the NOVA trial, niraparib was approved for the maintenance therapy of patients with recurrent ovarian cancer who fulfill the common criteria for platinum sensitivity.17 It was the first FDA-approved PARP inhibitor to be used in the maintenance setting and has since changed the standard of practice.